The pathogenicity of splicing defects: Mechanistic insights into pre-mRNA processing inform novel therapeutic approaches

EMBO Reports

Volumn 16, Issue 12, 2015, Pages 1640-1655

  Daguenet, Elisabeth ^a,b   Dujardin, Gwendal ^a,b   Valcárcel, Juan ^a,b,c  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

alternative splicing; disease; mutation; RNA; spliceosome

Indexed keywords

MESSENGER RNA PRECURSOR; OLIGONUCLEOTIDE; SMALL NUCLEAR RIBONUCLEOPROTEIN; TRANS ACTING FACTOR; MESSENGER RNA; RNA PRECURSOR;

ALTERNATIVE RNA SPLICING; BIOGENESIS; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOMICS; HUMAN; INTRON; METABOLIC SYNDROME X; MUSCULAR DYSTROPHY; NEOPLASM; NONHUMAN; PATHOGENICITY; PHYSIOLOGICAL PROCESS; PRECURSOR; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RNA PROCESSING; RNA SPLICING; SPLICING DEFECT; TRANS SPLICING; ANIMAL; DISEASES; EXON; GENETICS; METABOLISM; MUSCULAR DYSTROPHIES; MUTATION; NEOPLASMS; SPLICEOSOME;

ALTERNATIVE SPLICING; ANIMALS; DISEASE; EXONS; HUMANS; INTRONS; MUSCULAR DYSTROPHIES; MUTATION; NEOPLASMS; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER; SPLICEOSOMES;

EID: 84954305435     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201541116     Document Type: Review

References (168)

1. Moore MJ, Proudfoot NJ, (2009) Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136: 688-700
2. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ, (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40: 1413-1415
3. Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, Slobodeniuc V, Kutter C, Watt S, Colak R, et al, (2012) The evolutionary landscape of alternative splicing in vertebrate species. Science 338: 1587-1593
4. Merkin J, Russell C, Chen P, Burge CB, (2012) Evolutionary dynamics of gene and isoform regulation in Mammalian tissues. Science 338: 1593-1599
5. Cooper TA, Wan L, Dreyfuss G, (2009) RNA and disease. Cell 136: 777-793
6. Ward AJ, Cooper TA, (2010) The pathobiology of splicing. J Pathol 220: 152-163
7. Li DK, Tisdale S, Lotti F, Pellizzoni L, (2014) SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Semin Cell Dev Biol 32: 22-29
8. Biamonti G, Catillo M, Pignataro D, Montecucco A, Ghigna C, (2014) The alternative splicing side of cancer. Semin Cell Dev Biol 32: 30-36
9. Oltean S, Bates DO, (2014) Hallmarks of alternative splicing in cancer. Oncogene 33: 5311-5318
10. Linder B, Fischer U, Gehring NH, (2015) mRNA metabolism and neuronal disease. FEBS Lett 589: 1598-1606
11. Fredericks AM, Cygan KJ, Brown BA, Fairbrother WG, (2015) RNA-binding proteins: splicing factors and disease. Biomolecules 5: 893-909
12. Matera AG, Wang Z, (2014) A day in the life of the spliceosome. Nat Rev Mol Cell Biol 15: 108-121
13. Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E, Munoz MJ, (2013) Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 14: 153-165
14. Wahl MC, Will CL, Luhrmann R, (2009) The spliceosome: design principles of a dynamic RNP machine. Cell 136: 701-718
15. Wahl MC, Luhrmann R, (2015) SnapShot: spliceosome dynamics I. Cell 161: 1474-e1
16. Wahl MC, Luhrmann R, (2015) SnapShot: spliceosome dynamics II. Cell 162: 456-e1
17. Berget SM, (1995) Exon recognition in vertebrate splicing. J Biol Chem 270: 2411-2414
18. House AE, Lynch KW, (2006) An exonic splicing silencer represses spliceosome assembly after ATP-dependent exon recognition. Nat Struct Mol Biol 13: 937-944
19. Bonnal S, Martinez C, Forch P, Bachi A, Wilm M, Valcarcel J, (2008) RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell 32: 81-95
20. Sharma S, Maris C, Allain FH, Black DL, (2011) U1 snRNA directly interacts with polypyrimidine tract-binding protein during splicing repression. Mol Cell 41: 579-588
21. Will CL, Luhrmann R, (2011) Spliceosome structure and function. Cold Spring Harb Perspect Biol 3: a003707
22. Chen M, Manley JL, (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 10: 741-754
23. Fu XD, Ares M Jr, (2014) Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet 15: 689-701
24. Barash Y, Calarco JA, Gao W, Pan Q, Wang X, Shai O, Blencowe BJ, Frey BJ, (2010) Deciphering the splicing code. Nature 465: 53-59
25. Braunschweig U, Gueroussov S, Plocik AM, Graveley BR, Blencowe BJ, (2013) Dynamic integration of splicing within gene regulatory pathways. Cell 152: 1252-1269
26. Collins CA, Guthrie C, (1999) Allele-specific genetic interactions between Prp8 and RNA active site residues suggest a function for Prp8 at the catalytic core of the spliceosome. Genes Dev 13: 1970-1982
27. Nilsen TW, Graveley BR, (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature 463: 457-463
28. Clark TA, Sugnet CW, Ares M Jr, (2002) Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science 296: 907-910
29. Papasaikas P, Tejedor JR, Vigevani L, Valcarcel J, (2015) Functional splicing network reveals extensive regulatory potential of the core spliceosomal machinery. Mol Cell 57: 7-22
30. Tejedor JR, Papasaikas P, Valcarcel J, (2015) Genome-wide identification of Fas/CD95 alternative splicing regulators reveals links with iron homeostasis. Mol Cell 57: 23-38
31. Dujardin G, Lafaille C, Petrillo E, Buggiano V, Gomez Acuna LI, Fiszbein A, Godoy Herz MA, Nieto Moreno N, Munoz MJ, Allo M, et al, (2013) Transcriptional elongation and alternative splicing. Biochim Biophys Acta 1829: 134-140
32. Dujardin G, Lafaille C, de la Mata M, Marasco LE, Munoz MJ, Le Jossic-Corcos C, Corcos L, Kornblihtt AR, (2014) How slow RNA polymerase II elongation favors alternative exon skipping. Mol Cell 54: 683-690
33. Iannone C, Valcarcel J, (2013) Chromatin's thread to alternative splicing regulation. Chromosoma 122: 465-474
34. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T, (2011) Epigenetics in alternative pre-mRNA splicing. Cell 144: 16-26
35. Heyd F, Lynch KW, (2011) Degrade, move, regroup: signaling control of splicing proteins. Trends Biochem Sci 36: 397-404
36. Pagani F, Raponi M, Baralle FE, (2005) Synonymous mutations in CFTR exon 12 affect splicing and are not neutral in evolution. Proc Natl Acad Sci USA 102: 6368-6372
37. Serra E, Ars E, Ravella A, Sanchez A, Puig S, Rosenbaum T, Estivill X, Lazaro C, (2001) Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet 108: 416-429
38. Lim KH, Ferraris L, Filloux ME, Raphael BJ, Fairbrother WG, (2011) Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes. Proc Natl Acad Sci USA 108: 11093-11098
39. Padgett RA, (2012) New connections between splicing and human disease. Trends Genet 28: 147-154
40. Singh RK, Cooper TA, (2012) Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18: 472-482
41. Sterne-Weiler T, Howard J, Mort M, Cooper DN, Sanford JR, (2011) Loss of exon identity is a common mechanism of human inherited disease. Genome Res 21: 1563-1571
42. Gnad F, Baucom A, Mukhyala K, Manning G, Zhang Z, (2013) Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genom 14 (Suppl 3): S7
43. Sauna ZE, Kimchi-Sarfaty C, (2011) Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12: 683-691
44. Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B, (2014) Synonymous mutations frequently act as driver mutations in human cancers. Cell 156: 1324-1335
45. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RK, Hua Y, Gueroussov S, Najafabadi HS, Hughes TR, et al, (2015) RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science 347: 1254806
46. Sterne-Weiler T, Sanford JR, (2014) Exon identity crisis: disease-causing mutations that disrupt the splicing code. Genome Biol 15: 201
47. Mort M, Sterne-Weiler T, Li B, Ball EV, Cooper DN, Radivojac P, Sanford JR, Mooney SD, (2014) MutPred splice: machine learning-based prediction of exonic variants that disrupt splicing. Genome Biol 15: R19
48. Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, Ekstein J, Rubin BY, (2001) Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet 68: 753-758
49. Ibrahim EC, Hims MM, Shomron N, Burge CB, Slaugenhaupt SA, Reed R, (2007) Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia. Hum Mutat 28: 41-53
50. Carmel I, Tal S, Vig I, Ast G, (2004) Comparative analysis detects dependencies among the 5′ splice-site positions. RNA 10: 828-840
51. Cuajungco MP, Leyne M, Mull J, Gill SP, Lu W, Zagzag D, Axelrod FB, Maayan C, Gusella JF, Slaugenhaupt SA, (2003) Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. Am J Hum Genet 72: 749-758
52. Roca X, Krainer AR, (2009) Recognition of atypical 5′ splice sites by shifted base-pairing to U1 snRNA. Nat Struct Mol Biol 16: 176-182
53. Lopez-Mejia IC, Vautrot V, De Toledo M, Behm-Ansmant I, Bourgeois CF, Navarro CL, Osorio FG, Freije JM, Stevenin J, De Sandre-Giovannoli A, et al, (2011) A conserved splicing mechanism of the LMNA gene controls premature aging. Hum Mol Genet 20: 4540-4555
54. Scaffidi P, Misteli T, (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11: 440-445
55. Osorio FG, Navarro CL, Cadinanos J, Lopez-Mejia IC, Quiros PM, Bartoli C, Rivera J, Tazi J, Guzman G, Varela I, et al, (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3: 106ra107
56. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al, (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-705
57. Grover A, Houlden H, Baker M, Adamson J, Lewis J, Prihar G, Pickering-Brown S, Duff K, Hutton M, (1999) 5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem 274: 15134-15143
58. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, et al, (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155-165
59. Lorson CL, Hahnen E, Androphy EJ, Wirth B, (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96: 6307-6311
60. Monani UR, De Vivo DC, (2014) Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond. Future Neurol 9: 49-65
61. Cartegni L, Krainer AR, (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30: 377-384
62. Kashima T, Manley JL, (2003) A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 34: 460-463
63. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR, (2008) Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82: 834-848
64. Singh NK, Singh NN, Androphy EJ, Singh RN, (2006) Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26: 1333-1346
65. Singh NN, Singh RN, (2011) Alternative splicing in spinal muscular atrophy underscores the role of an intron definition model. RNA Biol 8: 600-606
66. Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim M, Dreyfuss G, (2008) SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133: 585-600
67. Lotti F, Imlach WL, Saieva L, Beck ES, Hao le T, Li DK, Jiao W, Mentis GZ, Beattie CE, McCabe BD, et al, (2012) An SMN-dependent U12 splicing event essential for motor circuit function. Cell 151: 440-454
68. Imlach WL, Beck ES, Choi BJ, Lotti F, Pellizzoni L, McCabe BD, (2012) SMN is required for sensory-motor circuit function in Drosophila. Cell 151: 427-439
69. Kariya S, Obis T, Garone C, Akay T, Sera F, Iwata S, Homma S, Monani UR, (2014) Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest 124: 785-800
70. Mahler M, (2011) Sm peptides in differentiation of autoimmune diseases. Adv Clin Chem 54: 109-128
71. Renton AE, Chio A, Traynor BJ, (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17: 17-23
72. Gerbino V, Carri MT, Cozzolino M, Achsel T, (2013) Mislocalised FUS mutants stall spliceosomal snRNPs in the cytoplasm. Neurobiol Dis 55: 120-128
73. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al, (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323: 1208-1211
74. Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, et al, (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208
75. Yamazaki T, Chen S, Yu Y, Yan B, Haertlein TC, Carrasco MA, Tapia JC, Zhai B, Das R, Lalancette-Hebert M, et al, (2012) FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep 2: 799-806
76. Groen EJ, Fumoto K, Blokhuis AM, Engelen-Lee J, Zhou Y, van den Heuvel DM, Koppers M, van Diggelen F, van Heest J, Demmers JA, et al, (2013) ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN. Hum Mol Genet 22: 3690-3704
77. Ishihara T, Ariizumi Y, Shiga A, Kato T, Tan CF, Sato T, Miki Y, Yokoo M, Fujino T, Koyama A, et al, (2013) Decreased number of Gemini of coiled bodies and U12 snRNA level in amyotrophic lateral sclerosis. Hum Mol Genet 22: 4136-4147
78. Ling JP, Pletnikova O, Troncoso JC, Wong PC, (2015) NEURODEGENERATION. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 349: 650-655
79. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al, (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133
80. Bai B, Hales CM, Chen PC, Gozal Y, Dammer EB, Fritz JJ, Wang X, Xia Q, Duong DM, Street C, et al, (2013) U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer's disease. Proc Natl Acad Sci USA 110: 16562-16567
81. Shchepachev V, Wischnewski H, Missiaglia E, Soneson C, Azzalin CM, (2012) Mpn1, mutated in poikiloderma with neutropenia protein 1, is a conserved 3′-to-5′ RNA exonuclease processing U6 small nuclear RNA. Cell Rep 2: 855-865
82. Arnold AW, Itin PH, Pigors M, Kohlhase J, Bruckner-Tuderman L, Has C, (2010) Poikiloderma with neutropenia: a novel C16orf57 mutation and clinical diagnostic criteria. Br J Dermatol 163: 866-869
83. Chantorn R, Shwayder T, (2012) Poikiloderma with neutropenia: report of three cases including one with calcinosis cutis. Pediatr Dermatol 29: 463-472
84. Clericuzio C, Harutyunyan K, Jin W, Erickson RP, Irvine AD, McLean WH, Wen Y, Bagatell R, Griffin TA, Shwayder TA, et al, (2011) Identification of a novel C16orf57 mutation in Athabaskan patients with Poikiloderma with Neutropenia. Am J Med Genet A 155A: 337-342
85. Colombo EA, Bazan JF, Negri G, Gervasini C, Elcioglu NH, Yucelten D, Altunay I, Cetincelik U, Teti A, Del Fattore A, et al, (2012) Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations. Orphanet J Rare Dis 7: 7
86. Concolino D, Roversi G, Muzzi GL, Sestito S, Colombo EA, Volpi L, Larizza L, Strisciuglio P, (2010) Clericuzio-type poikiloderma with neutropenia syndrome in three sibs with mutations in the C16orf57 gene: delineation of the phenotype. Am J Med Genet A 152A: 2588-2594
87. Volpi L, Roversi G, Colombo EA, Leijsten N, Concolino D, Calabria A, Mencarelli MA, Fimiani M, Macciardi F, Pfundt R, et al, (2010) Targeted next-generation sequencing appoints c16orf57 as clericuzio-type poikiloderma with neutropenia gene. Am J Hum Genet 86: 72-76
88. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, et al, (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365: 1384-1395
89. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, et al, (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478: 64-69
90. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, et al, (2012) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44: 47-52
91. Gozani O, Potashkin J, Reed R, (1998) A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol Cell Biol 18: 4752-4760
92. Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R, (1998) Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev 12: 1409-1414
93. Kfir N, Lev-Maor G, Glaich O, Alajem A, Datta A, Sze SK, Meshorer E, Ast G, (2015) SF3B1 association with chromatin determines splicing outcomes. Cell Rep 11: 618-629
94. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, Fangazio M, Vaisitti T, Monti S, Chiaretti S, et al, (2011) Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118: 6904-6908
95. Bernier FP, Caluseriu O, Ng S, Schwartzentruber J, Buckingham KJ, Innes AM, Jabs EW, Innis JW, Schuette JL, Gorski JL, et al, (2012) Haploinsufficiency of SF3B4, a component of the pre-mRNA spliceosomal complex, causes Nager syndrome. Am J Hum Genet 90: 925-933
96. McKerrell T, Park N, Moreno T, Grove CS, Ponstingl H, Stephens J, Understanding Society Scientific Group, Crawley C, Craig J, Scott MA, et al, (2015) Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep 10: 1239-1245
97. Ferreira PG, Jares P, Rico D, Gomez-Lopez G, Martinez-Trillos A, Villamor N, Ecker S, Gonzalez-Perez A, Knowles DG, Monlong J, et al, (2014) Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res 24: 212-226
98. Shirai CL, Ley JN, White BS, Kim S, Tibbitts J, Shao J, Ndonwi M, Wadugu B, Duncavage EJ, Okeyo-Owuor T, et al, (2015) Mutant U2AF1 expression alters hematopoiesis and Pre-mRNA splicing in vivo. Cancer Cell 27: 631-643
99. Lines MA, Huang L, Schwartzentruber J, Douglas SL, Lynch DC, Beaulieu C, Guion-Almeida ML, Zechi-Ceide RM, Gener B, Gillessen-Kaesbach G, et al, (2012) Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly. Am J Hum Genet 90: 369-377
100. Mordes D, Luo X, Kar A, Kuo D, Xu L, Fushimi K, Yu G, Sternberg P, Jr, Wu JY, (2006) Pre-mRNA splicing and retinitis pigmentosa. Mol Vis 12: 1259-1271
101. Neumann B, Walter T, Heriche JK, Bulkescher J, Erfle H, Conrad C, Rogers P, Poser I, Held M, Liebel U, et al, (2010) Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature 464: 721-727
102. Oka Y, Varmark H, Vitting-Seerup K, Beli P, Waage J, Hakobyan A, Mistrik M, Choudhary C, Rohde M, Bekker-Jensen S, et al, (2014) UBL5 is essential for pre-mRNA splicing and sister chromatid cohesion in human cells. EMBO Rep 15: 956-964
103. Sundaramoorthy S, Vazquez-Novelle MD, Lekomtsev S, Howell M, Petronczki M, (2014) Functional genomics identifies a requirement of pre-mRNA splicing factors for sister chromatid cohesion. EMBO J 33: 2623-2642
104. van der Lelij P, Stocsits RR, Ladurner R, Petzold G, Kreidl E, Koch B, Schmitz J, Neumann B, Ellenberg J, Peters JM, (2014) SNW1 enables sister chromatid cohesion by mediating the splicing of sororin and APC2 pre-mRNAs. EMBO J 33: 2643-2658
105. Watrin E, Demidova M, Watrin T, Hu Z, Prigent C, (2014) Sororin pre-mRNA splicing is required for proper sister chromatid cohesion in human cells. EMBO Rep 15: 948-955
106. Nguyen TH, Li J, Galej WP, Oshikane H, Newman AJ, Nagai K, (2013) Structural basis of Brr2-Prp8 interactions and implications for U5 snRNP biogenesis and the spliceosome active site. Structure 21: 910-919
107. Mozaffari-Jovin S, Wandersleben T, Santos KF, Will CL, Luhrmann R, Wahl MC, (2013) Inhibition of RNA helicase Brr2 by the C-terminal tail of the spliceosomal protein Prp8. Science 341: 80-84
108. Mozaffari-Jovin S, Wandersleben T, Santos KF, Will CL, Luhrmann R, Wahl MC, (2014) Novel regulatory principles of the spliceosomal Brr2 RNA helicase and links to retinal disease in humans. RNA Biol 11: 298-312
109. Edery P, Marcaillou C, Sahbatou M, Labalme A, Chastang J, Touraine R, Tubacher E, Senni F, Bober MB, Nampoothiri S, et al, (2011) Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. Science 332: 240-243
110. He H, Liyanarachchi S, Akagi K, Nagy R, Li J, Dietrich RC, Li W, Sebastian N, Wen B, Xin B, et al, (2011) Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science 332: 238-240
111. Madan V, Kanojia D, Li J, Okamoto R, Sato-Otsubo A, Kohlmann A, Sanada M, Grossmann V, Sundaresan J, Shiraishi Y, et al, (2015) Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat Commun 6: 6042
112. David CJ, Manley JL, (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24: 2343-2364
113. Bonnal S, Vigevani L, Valcarcel J, (2012) The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov 11: 847-859
114. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR, (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14: 185-193
115. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S, Biamonti G, (2005) Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 20: 881-890
116. Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, Li Y, Chung YR, Micol JB, Murphy ME, et al, (2015) SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27: 617-630
117. Komeno Y, Huang YJ, Qiu J, Lin L, Xu Y, Zhou Y, Chen L, Monterroza DD, Li H, DeKelver RC, et al, (2015) SRSF2 is essential for hematopoiesis and its myelodysplastic syndromes-related mutations dysregulate alternative pre-mRNA splicing. Mol Cell Biol 35: 3071-3082
118. Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, Raza A, Mukherjee S, Manley JL, et al, (2015) A disease-associated mutation in SRSF2 misregulates splicing by altering RNA binding affinities. Proc Natl Acad Sci USA 112: E4726-E4734
119. David CJ, Chen M, Assanah M, Canoll P, Manley JL, (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368
120. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al, (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120
121. Bechara EG, Sebestyen E, Bernardis I, Eyras E, Valcarcel J, (2013) RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell 52: 720-733
122. Wang Y, Gogol-Doring A, Hu H, Frohler S, Ma Y, Jens M, Maaskola J, Murakawa Y, Quedenau C, Landthaler M, et al, (2013) Integrative analysis revealed the molecular mechanism underlying RBM10-mediated splicing regulation. EMBO Mol Med 5: 1431-1442
123. Irimia M, Weatheritt RJ, Ellis JD, Parikshak NN, Gonatopoulos-Pournatzis T, Babor M, Quesnel-Vallieres M, Tapial J, Raj B, O'Hanlon D, et al, (2014) A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell 159: 1511-1523
124. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, Neville C, Narang M, Barcelo J, O'Hoy K, et al, (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 255: 1253-1255
125. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, Day JW, Ranum LP, (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293: 864-867
126. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, Moxley RT, Swanson MS, Thornton CA, (2006) Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 15: 2087-2097
127. Kuyumcu-Martinez NM, Wang GS, Cooper TA, (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28: 68-78
128. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA, (2002) Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 10: 45-53
129. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA, (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10: 35-44
130. Savkur RS, Philips AV, Cooper TA, (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29: 40-47
131. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA, (2007) Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117: 3952-3957
132. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James A, Groot N, et al, (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983
133. Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, et al, (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci USA 110: 2366-2370
134. Kaida D, Berg MG, Younis I, Kasim M, Singh LN, Wan L, Dreyfuss G, (2010) U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation. Nature 468: 664-668
135. Fernandez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, Hernandez F, Avila J, Lucas JJ, (2014) Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20: 881-885
136. Yin X, Jin N, Gu J, Shi J, Zhou J, Gong CX, Iqbal K, Grundke-Iqbal I, Liu F, (2012) Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion. J Biol Chem 287: 30497-30506
137. Kole R, Krainer AR, Altman S, (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11: 125-140
138. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR, (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24: 1634-1644
139. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR, (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478: 123-126
140. Benchaouir R, Robin V, Goyenvalle A, (2015) Gene and splicing therapies for neuromuscular diseases. Front Biosci (Landmark Ed) 20: 1190-1233
141. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, Thornton CA, (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325: 336-339
142. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA, (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488: 111-115
143. Brun C, Suter D, Pauli C, Dunant P, Lochmuller H, Burgunder JM, Schumperli D, Weis J, (2003) U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. Cell Mol Life Sci 60: 557-566
144. Vulin A, Barthelemy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, Benchaouir R, le Hir M, Unterfinger Y, Lorain S, et al, (2012) Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 20: 2120-2133
145. Fernandez Alanis E, Pinotti M, Dal Mas A, Balestra D, Cavallari N, Rogalska ME, Bernardi F, Pagani F, (2012) An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects. Hum Mol Genet 21: 2389-2398
146. Nizzardo M, Simone C, Dametti S, Salani S, Ulzi G, Pagliarani S, Rizzo F, Frattini E, Pagani F, Bresolin N, et al, (2015) Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches. Sci Rep 5: 11746
147. Cartegni L, Krainer AR, (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 10: 120-125
148. Meyer K, Marquis J, Trub J, Nlend Nlend R, Verp S, Ruepp MD, Imboden H, Barde I, Trono D, Schumperli D, (2009) Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum Mol Genet 18: 546-555
149. Gingeras TR, (2009) Implications of chimaeric non-co-linear transcripts. Nature 461: 206-211
150. Wu CS, Yu CY, Chuang CY, Hsiao M, Kao CF, Kuo HC, Chuang TJ, (2014) Integrative transcriptome sequencing identifies trans-splicing events with important roles in human embryonic stem cell pluripotency. Genome Res 24: 25-36
151. Yang Y, Walsh CE, (2005) Spliceosome-mediated RNA trans-splicing. Mol Ther 12: 1006-1012
152. Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, Cohn JA, Garcia-Blanco MA, Mitchell LG, Engelhardt JF, (2002) Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 20: 47-52
153. Coady TH, Shababi M, Tullis GE, Lorson CL, (2007) Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol Ther 15: 1471-1478
154. Lorain S, Peccate C, Le Hir M, Griffith G, Philippi S, Precigout G, Mamchaoui K, Jollet A, Voit T, Garcia L, (2013) Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches. Nucleic Acids Res 41: 8391-8402
155. Berger A, Lorain S, Josephine C, Desrosiers M, Peccate C, Voit T, Garcia L, Sahel JA, Bemelmans AP, (2015) Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa. Mol Ther 23: 918-930
156. Webb TR, Joyner AS, Potter PM, (2013) The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today 18: 43-49
157. Lagisetti C, Palacios G, Goronga T, Freeman B, Caufield W, Webb TR, (2013) Optimization of antitumor modulators of pre-mRNA splicing. J Med Chem 56: 10033-10044
158. Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM, (2011) Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol 6: 582-589
159. Salton M, Kasprzak WK, Voss T, Shapiro BA, Poulikakos PI, Misteli T, (2015) Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun 6: 7103
160. Corrionero A, Minana B, Valcarcel J, (2011) Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev 25: 445-459
161. Roybal GA, Jurica MS, (2010) Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation. Nucleic Acids Res 38: 6664-6672
162. Folco EG, Coil KE, Reed R, (2011) The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. Genes Dev 25: 440-444
163. Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG, et al, (2014) Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345: 688-693
164. Palacino J, Swalley SE, Song C, Cheung AK, Shu L, Zhang X, Van Hoosear M, Shin Y, Chin DN, Keller CG, et al, (2015) SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol 11: 511-517
165. Axelrod FB, Liebes L, Gold-Von Simson G, Mendoza S, Mull J, Leyne M, Norcliffe-Kaufmann L, Kaufmann H, Slaugenhaupt SA, (2011) Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res 70: 480-483
166. Liu B, Anderson SL, Qiu J, Rubin BY, (2013) Cardiac glycosides correct aberrant splicing of IKBKAP-encoded mRNA in familial dysautonomia derived cells by suppressing expression of SRSF3. FEBS J 280: 3632-3646
167. Yoshida M, Kataoka N, Miyauchi K, Ohe K, Iida K, Yoshida S, Nojima T, Okuno Y, Onogi H, Usui T, et al, (2015) Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. Proc Natl Acad Sci USA 112: 2764-2769
168. Zheng S, Chen Y, Donahue CP, Wolfe MS, Varani G, (2009) Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). Chem Biol 16: 557-566